Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Robert B. Ford

At a glance: Robert B. Ford is CEO, Chair at Abbott Laboratories (ABT). Their latest SEC Form 4, filed Aug 27, 2026, reported a sale of $25.3M. On file: 1 purchase line ($2.0M) and 2 sale lines ($46.2M).

Disclosed holdings: about $54.4M of ABT stock: 522,664 shares (including shares held indirectly, e.g. through a trust or fund) reported on their latest Form 4 (filed Aug 27, 2026), valued at the Nov 20, 2026 close of $104.17. This counts only ABT shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO, Chair at Abbott Laboratories (ABT)

Purchase track record

Not enough history. Based on 1 purchase with a full 90 days of price history.

—
Avg. 90-day return-14.1%
vs. S&P 500-17.7%
Beat the market0%
Paper profit on buys−$56K
Total bought / sold$2.0M / $46.2M

Robert B. Ford's InsiderPrint

3 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.

InsiderPrint of Robert B. Ford: 3 trades, 2026 to 20262026: 1 buy, 2 sales

Reading this print: Mostly sells, trading about 3 times a year, typically $20.9M a trade; often buys after the stock has fallen 15% or more.

  • Bump outward: a purchase (1)
  • Dent inward: a sale (2)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. David Baxley SpetzlerPresident · CAI · 98% match
  2. Sergey YezhkovSvp/Co-Head Of Global Business · EPAM · 96% match
  3. Eric J. DugasCFO · CLH · 95% match
  4. Susan Cohen LevyGeneral Counsel · NTRS · 95% match
  5. Vivek Ramaswamy10% Owner · ROIV · 94% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2026

From the SEC's insider data sets: each open-market buy by Robert B. Ford, matched to how the stock did over the next 90 days against the S&P 500.

0 of 1 buy beat the S&P 500 (0%), median -27.2% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
ABTFeb 6, 2026-27.2%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Aug 27SEC ABTAbbott Laboratories Sell 218,535486,758 held (−31%) $115.57 $25.3M -9.9%
Aug 27SEC ABTAbbott Laboratories Sell 180,297306,461 held (−37%) $116.19 $20.9M -10.3%
Jan 26SEC ABTAbbott LaboratoriesFirst buy Buy 18,800216,203 held (+10%) $107.13 $2.0M -2.8%
  • Sell

    CEO, Chair Robert B Ford sold $25.3M of ABT at $115.57 — cuts the stake by 31%.

  • Sell

    CEO, Chair Robert B Ford sold $20.9M of ABT at $116.19 — cuts the stake by 37%.

  • Buy

    CEO, Chair Robert B Ford bought $2.0M of ABT at $107.13 — first open-market purchase in our records.

Follow Robert B. Ford

Get one email when Robert B. Ford files a new purchase or sale. Free.

At most one email a day about Robert B. Ford, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.